

Detection and quantification of mutations in the plasma of patients with colorectal tumors

Frank Diehl*, Meng Li*, Devin Dressman*, Yiping He*, Dong Shen*, Steve Szabo*, Luis A. Diaz, Jr., Steven N. Goodman*, Kerstin A. David†, Hartmut Juhl†, Kenneth W. Kinzler*, and Bert Vogelstein**

*Howard Hughes Medical Institute and The Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins Medical Institutions, 1650 Orleans Street, Baltimore, MD 21231; and †Indivumed, Center for Cancer Research at Israelitic Hospital, Orchideenstieg 14, 22297 Hamburg, Germany

Contributed by Bert Vogelstein, September 16, 2005

The early detection of cancers through analysis of circulating DNA could have a substantial impact on morbidity and mortality. To achieve this goal, it is essential to determine the number of mutant molecules present in the circulation of cancer patients and to develop methods that are sufficiently sensitive to detect these mutations. Using a modified version of a recently developed assay for this purpose, we found that patients with advanced colorectal cancers consistently contained mutant adenomatous polyposis coli (APC) DNA molecules in their plasma. The median number of APC DNA fragments in such patients was 47,800 per ml of plasma, of which 8% were mutant. Mutant APC molecules were also detected in >60% of patients with early, presumably curable colorectal cancers, at levels ranging from 0.01% to 1.7% of the total APC molecules. These results have implications for the mechanisms through which tumor DNA is released into the circulation and for diagnostic tests based on this phenomenon.

colorectal cancer | plasma DNA | tumor suppressor gene | circulating DNA | diagnosis

The probability of curing cancers through surgery alone is high in individuals whose primary tumors are detected at a relatively early stage. Such early detection is therefore one of the most promising approaches for limiting cancer morbidity and mortality in the future (1). At present, Pap smears can be used to detect cervical cancers, mammography can detect breast cancers, serum PSA (prostate-specific antigen) levels can signify the presence of prostate cancer, and colonoscopy and fecal occult blood tests can detect colon cancers (2). However, problems with sensitivity, specificity, cost, or compliance have complicated widespread implementation of many of these tests (3–5). Moreover, methods for the early detection of most other cancer types are not yet available.

The discovery of the genetic bases of neoplasia has led to new approaches to detect tumors noninvasively (6–8). Several of these approaches rely on the *ex vivo* detection of mutant forms of the oncogenes and tumor suppressor genes that are responsible for the initiation and progression of tumors. This approach was first used to detect bladder and colon tumors through examination of urine and stool, respectively (9, 10), and has since been used to detect several other tumor types (11–14). Because the mutant genes are not only “markers” for cancer but also the proximate causes of tumor growth (1), they have major conceptual advantages over conventional markers such as fecal occult blood or serum PSA. In particular, conventional markers are not pathogenically involved in the tumorigenic process and are much less specific for neoplasia than are mutations.

The evaluation of patient blood samples for mutant DNA molecules is a particularly attractive approach because such tests could detect many different forms of cancers. Additionally, blood can be easily obtained from patients during routine outpatient visits, and methods for preparing and storing plasma and serum are well known and reliable. Accordingly, numerous studies have attempted to identify abnormal forms or quantities of DNA in plasma or serum (6, 11–15). Unfortunately, the results of many of

these studies are contradictory. Some report high detection rates of cancers, and others report very low detection rates, despite the use of similar techniques and patient cohorts. Moreover, several studies have shown that loss of heterozygosity is routinely detectable in circulating DNA, even in patients with relatively nonaggressive tumors. To detect loss of heterozygosity in such samples, the neoplastic cells within a tumor must contribute >50% of the total circulating DNA.

The above studies, although promising, lead to several questions that must be answered to engender confidence in the use of circulating, abnormal DNA as a biomarker of malignancy. First, how many copies of a given gene fragment are present in the circulation in cancer patients? Second, what is the nature of this DNA (e.g., intact vs. degraded)? Third, what fraction of these gene fragments have an abnormal (e.g., mutant) DNA sequence? And, fourth, how does this fraction vary with stage of disease? To answer these questions, it was necessary to develop technologies that could simultaneously quantify the number of normal and mutant DNA molecules in a given sample, even when the fraction of mutant molecules was very small. In the current study, we employ such a technology to investigate circulating DNA in patients with colorectal tumors.

Materials and Methods

Sample Collection, DNA Extraction, and Sequencing. Detailed methods for these procedures are provided in the supporting information, which is published on the PNAS web site.

Real-Time PCR. Primers were designed to generate ≈100-bp amplicons that included one or more mutation sites. A universal tag (5'-TCCCGCGAAATTAATACGAC-3') was added to the 5' end of either the forward or reverse primer used to generate each amplicon. The sequences of these primers are listed in the supporting information. PCR was performed in 50- μ l reactions containing 10 μ l of 5 \times Phusion HF buffer, a 0.2 mM concentration of each dNTP, a 1 μ M concentration of each primer, 1:50,000 dilution of SYBR green I (Invitrogen), 1.5 units of Phusion DNA polymerase (NEB, Beverly, MA), and 15 μ l of purified plasma DNA (equivalent to 100 μ l of plasma) or genomic DNA purified from normal mononuclear cells of the blood of healthy volunteers. The amplifications were carried out with an iCycler (Bio-Rad) under the following conditions: 98°C for 1 min; 98°C for 10 s, 70°C for 10 s, and 72°C for 10 s 3 times; 98°C for 10 s, 67°C for 10 s, and 72°C for 10 s 3 times; 98°C for 10 s, 64°C for 10 s, and 72°C for 10 s 3 times;

Conflict of interest statement: Under a licensing agreement between EXACT Sciences and The Johns Hopkins University, K.W.K. and B.V. are entitled to a share of royalties received by the university on sales of products related to digital PCR. Under a licensing agreement between Agencourt Biosciences Corporation and The Johns Hopkins University, D.D., K.W.K., and B.V. are entitled to a share of royalties received by the university on sales of products related to the use of BEAMing for preparing templates for DNA sequencing. The terms of these arrangements are being managed by The Johns Hopkins University in accordance with its conflict of interest policies.

Abbreviations: APC, adenomatous polyposis coli; PE, phycoerythrin.

†To whom correspondence should be addressed. E-mail: vogelbe@jhmi.edu.

© 2005 by The National Academy of Sciences of the USA

MAY 21, 2002

Table 1. Quantification of APC mutations in plasma

Patient no.	Sex/ age, yr	Site	Dukes' stage (tumor node metastasis stage)	Diameter of lesion, cm	Mutation identified in primary tumor (codon)	Fragments per ml of plasma	No. of fragments analyzed	Percentage of mutant fragments, %
1	M/50	Ascending colon	Adenoma	3.0	C4348T (1450)	2,600	2,350	0.002
2	M/67	Descending colon	Adenoma	2.5	C4285T (1429)	5,080	5,080	0.001
3	M/54	Rectum	Adenoma	4.0	G3856T (1286)	4,150	4,150	0.002
4	F/82	Rectum	Adenoma	3.0	4147–4148insA (1383)	1,350	1,350	0.001
5	F/65	Rectum	Adenoma	1.0	C4067G (1356)	4,260	4,260	0.001
6	F/71	Ascending colon	Adenoma	4.0	G3856T (1286)	4,150	4,150	0.001
7	M/68	Cecum	Adenoma	6.5	C4285T (1429)	4,760	4,760	0.003
8	M/93	Ascending colon	Adenoma	0.8	A4345T (1449)	4,320	4,320	0.001
9	F/78	Ascending colon	Adenoma	3.0	C4216T (1406)	28,570	28,570	0.001
10	F/59	Sigmoid colon	Adenoma	5.0	4661–4662insA (1554)	2,160	2,160	0.002
11	F/73	Ascending colon	Adenoma	5.0	C4348T (1450)	8,000	8,000	0.02
Median/mean						4,300/6,300		0.02*
Mutant plasma samples per samples analyzed								1/11 (9)
12	F/81	Sigmoid colon	A (T2N0M0)	4.0	G4189T (1397)	7,900	12,000	0.01
13	F/75	Sigmoid colon	A (T2N0M0)	2.5	3927–3931del AAAGA (1309)	2,160	2,160	0.001
14	M/60	Sigmoid colon	A (T2N0M0)	3.0	3927–3931del AAAGA (1309)	4,600	6,900	0.04
15	M/79	Right colic flexure	A (T2N0M0)	3.0	4470delT (1490)	4,600	3,696	0.03
16	M/70	Ileocecal	A (T2N0M0)	2.5	4481delA (1494)	6,200	3,105	0.07
17	F/68	Ascending colon	A (T2N0M0)	3.5	C4348T (1450)	2,170	2,170	0.001
18	F/66	Sigmoid colon	A (T1N0M0)	2.5	3927–3931del AAAGA (1309)	1,920	1,920	0.001
19	M/68	Rectum	A (T2N0M0)	5.5	C3907T (1303)	2,300	1,170	0.12
Median/mean						3,500/4,000		0.04/0.04*
Mutant plasma samples per samples analyzed								5/8 (63)
20	F/65	Cecum	B (T3N0M0)	3.5	G4396T (1466)	5,300	5,300	0.002
21	M/71	Sigmoid colon	B (T3N0M0)	3.0	C4348T (1450)	2,100	1,863	0.19
22	M/37	Descending colon	B (T4N0M0)	10.0	C4330T (1444)	5,400	4,887	1.28
23	M/64	Sigmoid colon	B (T3N0M0)	6.5	C4099T (1367)	3,810	3,810	0.001
24	M/72	Sigmoid colon	B (T3N0M0)	3.0	C4012T (1338)	4,800	4,800	0.03
25	F/82	Hepatic flexure	B (T3N0M0)	4.0	C4099T (1367)	3,840	3,840	1.46
26	M/83	Ascending colon	B (T3N0M0)	6.0	4470delT (1490)	1,600	1,404	1.75
27	M/61	Sigmoid colon	B (T3N0M0)	4.0	4260–4261delCA (1420)	4,200	4,200	0.001
Median/mean						4,000/3,900		1.28/0.94*
Mutant plasma samples per samples analyzed								5/8 (63)
28	F/83	Ascending colon	D (T3N2M1)	5.0	4661–4662insA (1554)	230,000	24,857	5.6
29	M/55	Sigmoid colon	D (T3N0M1)	3.0	G3925T (1309)	69,600	1,636	27.4
30	F/33	Descending colon	D (T4N1M1)	5.0	C4067A (1356)	18,000	491	10.5
31	M/64	Sigmoid colon	D (T4N2M1)	6.0	T4161A (1387)	26,000	975	1.9
32	M/56	Rectum	D (T3N2M1)	3.0	4468–4469delCA (1490)	103,200	1,187	18.9
33	F/60	Rectum	D (T3N2M1)	4.0	4059–4060insT (1354)	8,400	850	2.0
Median/mean						47,800/75,900		8.05/11.05*
Mutant plasma samples per samples analyzed								6/6 (100)

*Calculated only for samples in which the percentage of mutant fragments was significantly higher than in control samples (i.e., >0.003%; printed in boldface). M, male; F, female.

at speeds of >50,000 beads per s, the capacity to enumerate such mutations is not limited by the beads themselves. Instead, two other features limit the sensitivity. First, there is a finite number of DNA fragments present in clinical samples. As noted above, this number ranged from 1,350 to 230,000 fragments per ml in the patients with tumors (Table 1) and from 1,150 to 8,280 fragments per ml in control patients, which gives an upper bound to the sensitivity of the assays. For example, a calculation using the Poisson distribution shows that if 4,000 fragments were

analyzed, the mutation fraction in circulating DNA would have to be >1 in 1,333 fragments (i.e., 3 divided by the number of total fragments analyzed) for the assay to achieve 95% sensitivity. A second limiting feature is the error rates of the polymerases used for PCR. In our approach, two PCR steps are used: The first is a conventional PCR that employs plasma DNA fragments as templates, and the second is an oil-in-water emulsion PCR that uses the initial PCR products as templates. In the emulsion PCR, errors occurring during the early rounds of PCR can result in




Fig. 1. Effect of the PCR amplicon size on plasma DNA concentration and mutation frequency. (A) The concentration of total *APC* fragments (WT plus mutant) of various sizes was determined by using digital PCR of plasma DNA from three different patients (patients 29, 30, and 32). (B) The fraction of mutant *APC* fragments was determined by digital sequencing of PCR products.

heterogeneous beads containing both WT and mutant sequences. These beads are easily eliminated from consideration, as described in Fig. 3C. However, the errors introduced in the first PCR cannot be eliminated, because they give rise to beads with homogeneous mutant sequences, indistinguishable from those resulting from genuine mutations in the original plasma DNA templates.

The fraction of mutant molecules present after the first PCR equals the product of the mutation rate of the polymerase and the number of cycles carried out. BEAMing provides a quantitative way to determine the error rate of any polymerase used in PCR without requiring cloning in bacterial vectors (M.L., F.D., S.N.G., K.W.K., and B.V., unpublished data). Of 19 different base changes evaluated in normal DNA, the error rates with the polymerase used in the current study averaged 3.0×10^{-7} mutations per bp per PCR cycle and ranged from 1.7×10^{-7} to 6.5×10^{-7} mutations per bp per PCR cycle, depending on the mutation site assessed. As a result, we only scored plasma samples as positive for mutations if their frequency in the sample was significantly higher than the maximum error rate of polymerase found experimentally (i.e., 1.95×10^{-5} after 30 cycles). As a result of the relatively low error rate with the polymerase used, it was the number of molecules present in the original plasma sample, rather than the polymerase error rate *per se*, that limited sensitivity.

These issues suggest that the sensitivity of assays for circulating mutant DNA could be increased in the future by (i) the development of new or modified polymerases with reduced error rates and (ii) the use of more plasma per assay (i.e., more template molecules).




Fig. 3. Processing of flow cytometry data obtained by BEAMing. (A) Dot plot of forward-scatter (FSC) and side-scatter (SSC) signals of beads. (B) Histogram of single beads with regard to PE signal. (C) Dot plot showing the Cy5 and FITC fluorescence intensity profiles of PE-positive beads. The beads clustered in three distinct populations colored red, green, and blue. Sequencing of individual beads sorted from each population showed that the red and green beads contained homogeneous WT and mutant sequences, respectively; the blue beads contained a mixture of WT and mutant sequences.

Quantification of Mutant *APC* Fragments in Plasma from Patients with Colorectal Tumors. Based on the principles derived from the experiments described above, we determined whether fragments of tumor DNA could be detected in patients with colorectal tumors of various types. We selected *APC* gene mutations for this assessment, because >85% of colorectal tumors contain mutations of this gene, irrespective of tumor stage (23). Mutations within codon 1209–1581 of *APC*, containing most previously identified mutations, were evaluated by sequencing of DNA purified from the tumors of 56 patients. Mutations were observed in 33 of these patients (59%), and, as expected, the proportion of tumors with these mutations did not differ significantly among tumors of various stages (see the supporting information).

A BEAMing assay was then designed for each of the mutations identified in the 33 tumors and applied to the DNA purified from the plasma of the corresponding patients (Table 1). In each case, DNA from normal lymphocytes or plasma from patients without




Fig. 2. Schematic of the BEAMing-based assay. (A) Extended beads were prepared by modifications of the BEAMing procedure described by Dressman *et al.* (16). (B) Single base extensions were performed on the extended beads. Normal DNA sequences contained a G at the queried position; mutant sequences contained an A.

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.